Phase II Clinical Study of GemOX Hepatic Arterial Infusion Combined with Lenvatinib and Toripalimab for Advanced and Unresectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer

Inclusion Criteria 1. Age 18 or above 2. Histopathological or cytological diagnosis of intrahepatic cholangiocarcinoma or gallbladder cancer 3. A tumor that cannot be removed by three independent surgeons. 4. Expected lifespan ≥ 12 weeks 5. ECOG PS score 0-1 points 6. The patient voluntarily participates and signs an informed consent form; 7. Expected compliance is good, able to follow up on efficacy and adverse reactions according to the protocol requirements. Exclusion criteria: 1. Use any systemic research anti-cancer drugs 2. Active autoimmune diseases or a history of autoimmune diseases (such as interstitial pneumonia, uveitis, enteritis, hepatitis, pituitary inflammation, vasculitis, myocarditis, nephritis, hyperthyroidism, hypothyroidism (which may include hormone replacement therapy) 3. Asthma requires the use of bronchodilators for medical intervention 4. Congenital or acquired immune dysfunction, such as human immunodeficiency virus (HIV) infection 5. Clinical symptoms or uncontrolled heart disease 6. Severe infection within 4 weeks before the first use of medication 7. History of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation 8. Vaccination with attenuated live vaccine within 4 weeks before treatment 9. Other systemic malignant tumors in the past 5 years